

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 200130.503/1615.002		APPLICATION NO. 09/640,041	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS W. Michael Kavanaugh et al.			
				FILING DATE August 15, 2000		GROUP ART UNIT 1645	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	CLASS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MJ	AA	4,959,314	9/25/90	Mark et al.	435	69.1	
	AB						
	AC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
MJ	AD	WO 99/02681	1/21/99	WIPO			
	AE						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
MJ	AF	Burden and Yarden, "Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis," <i>Neuron</i> 18: 847-855, June 1997.					
	AG	Ben-Baruch et al., <i>Hormones and Growth Factors in Development and Neoplasia</i> , Wiley-Liss, Inc., Academic Publishers: Boston, 1998, Chapter 8, "Developmental and Physiologic Roles of ErbB Receptors and Their Ligands in Mammals," pp. 145-168.					
	AH	Carraway III et al., "Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with <i>erbB2/neu</i> and <i>erbB3</i> ," <i>The Journal of Biological Chemistry</i> 270(13): 7111-7116, March 31, 1995.					
	AI	Carraway III, K., "Involvement of the neuregulins and their receptors in cardiac and neural development," <i>BioEssays</i> 18(4): 263-266, 1996.					
	AJ	Carraway III and Burden, "Neuregulins and their receptors," <i>Current Opinion in Neurobiology</i> 5: 606-612, 1995.					
	AK	Carraway III et al., "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases," <i>Nature</i> 387: 512-516, May 1997.					
	AL	Carroll et al., "Expression of Neuregulins and their Putative Receptors, ErbB2 and ErbB3, Is Induced during Wallerian Degeneration," <i>The Journal of Neuroscience</i> 17(5): 1642-1659, March 1997.					
EXAMINER M.E. Jamney				DATE CONSIDERED 2/1/02			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

RECEIVED
 APR 02 2001
 TECH CENTER 1600/2900

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 200130.503/1615.002		APPLICATION NO. 09/640,041	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS W. Michael Kavanaugh et al.			
				FILING DATE August 15, 2000		GROUP ART UNIT 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
BA							
BB							
BC							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION	
						YES	NO
BD							
BE							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
MS	BF	Gassmann et al., "Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor," <i>Nature</i> 378: 390-394, November 1995. ✓					
	BG	Harari et al., "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase," <i>Oncogene</i> 18: 2681-2689, 1999. ✓					
	BH	Lee et al., "Requirement for neuregulin receptor erbB2 in neural and cardiac development," <i>Nature</i> 378: 394-398, November 23, 1995. ✓					
	BI	Meyer and Birchmeier, "Multiple essential functions of neuregulin in development," <i>Nature</i> 378: 386-390, November 23, 1995. ✓					
	BJ	Morrissette et al., "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2," <i>Proceedings of the National Academy of Science USA</i> 92: 1431-1435, February 1995. ✓					
	BK	Peles and Yarden, "Neu and its Ligands: From an Oncogene to Neural Factors," <i>BioEssays</i> 15(12): 815-824, December 1993. ✓					
	BL	Pinkas-Kramarski et al., "ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network," <i>Molecular and Cellular Biology</i> 18(10): 6090-6101, October 1998. ✓					
EXAMINER M.E. Jamoy				DATE CONSIDERED 2/1/02			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

 RECEIVED
 APR 02 2001
 PATENT CENTER 1600/2900

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 200130.503/1615.002		APPLICATION NO. 09/640,041	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS W. Michael Kavanaugh et al.			
				FILING DATE August 15, 2000		GROUP ART UNIT 1645	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
CA							
CB							
CC							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION YES NO	
CD							
CE							
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
MJ	CF	Pinkas-Kramarski et al., "Brain neurons and glial cells express Neu differentiation factor/hergulin: A survival factor for astrocytes," <i>Proceedings of the National Academy of Science USA</i> 91: 9387-9391, September 1994. ✓					
	CG	Tzahar et al., "ErbB-3 and ErbB-4 Function as the Respective Low and High Affinity Receptors of All Neu Differentiation Factor/hergulin Isoforms," <i>The Journal of Biological Chemistry</i> 269(40): 25226-25233, October 7, 1994. ✓					
	CH	Zhang et al., "Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4," <i>Proceedings of the National Academy of Science</i> 94: 9562-9567, September 1997. ✓					
	CI						
	CJ						
	CK						
	CL						
	CM						
	CN						
EXAMINER M. E. Jamison				DATE CONSIDERED 2/1/02			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

 RECEIVED
 APR 02 2001
 TECH CENTER 1600/2900